

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (August 2004) and Supplement 2 (November 2004) are preceded, respectively, by S1: and S2::

- Abbott, K.C., 353
Abe, M., 224
Acar, B., 2:E22
Adaimy, M., 636
Adler, S.G., 309
Afolabi, A., 363
Agmon, D., xlv, 6:E91
Agodoa, L.Y., 353
Ahmed, J., 498
Ahmed, M.S., 429
Akiba, T., 293, 661, 680, S2:34
Akizawa, T., 94, S2:27
Al-Absi, A.I., 4:E73
Albert, J.M., S2:34
Allon, M., 779, 859
Almpanis, C., 2:E25
Alvestrand, A., 455
Amin, M.G., 198
Amoroso, A., 987
Anderson, S., 1110
Anderstam, B., 455
Andrés, E., 4:E59
Andreucci, M., 257
Andreucci, V.E., 1024, S2:61
Angeles, C., 543
Aoki, T., 680
Ariano, R., 559
Arita, M., 112
Arjane, P., 877
Armitage, A., 121
Arons, R., 185
Arruda, J.A.L., 1031
Asakimori, Y., 112
Asano, Y., 94, S2:39
Åsberg, A., 84
Ascani, S., 757
Asif, A., 12
Atkins, R.C., 792
Attanasio, M., 611
Augustine, J.J., 1000
AusDiab Study Group, 792
Avesani, C.M., 1008
Ayanian, J.Z., 344, 1083
Aydin, Z., 179
Azap, A., 4:E47, 4:xlvii

Baccarani, M., 757
Bagnis, C.I., 1
Baigent, C., 382
Balkau, B., 792
Balletta, M.M., 1024
Bammens, B., 278
Ban, S., 902

Bárány, P., 455
Barbey, F., 799
Barbosa, D., 337
Barbour, G., 353
Barbouti, A., 286
Bardaji, A., 216
Barker, J., 859
Barth, K., 1017
Barth, R.H., 941
Barzilay, J.I., 25
Basadonna, G., 529
Bass, E.B., 695
Battaglia, M., 886
Baumelou, A., 1
Becker, B.N., 71
Belasco, A., 337
Bell, J.M., 618
Berman, E., 488
Besarab, A., 498, S2:22
Bestoso, J.T., 3:E43
Blaum, C., 25
Blazing, M.A., 207
Bleasel, K., 4:E68
Bloomfield, H., 832
Bohen, E.M., 353
Bommer, J., 94, 293, 661, S2:54
Bonner, G., xlvi, 6:E91
Borge, M.A., 429
Borgh, L., 963
Boujaoude, Z., 636
Braden, G.L., 4:E50
Bragg-Gresham, J.L., 61, 94, 293, S2:54
Bräsen, J.-H., 930
Brass, E.P., 309
Braun, N., 385
Braun, S., 627
Brewster, U.C., 5:E81
Brophy, D.F., 270
Brown, W.W., S2:22
Bruijn, J.A., 179, 773
Busque, S., 877

Cáceres-Alvarado, N., 2:E28
Caglioti, A., 257
Camargo, L., 337
Cameron, M.A., 1:E7
Canaud, B.J., S2:47
Cantarovich, F., 402
Cao, J.J., 25
Cardio-Renal Responder Group and Validation Cohort, 309
Caridi, G., 987

Cariolou, M., 300
Carr, M.E. Jr., 270
Carvalho, A.B., 747
Casari, G., 963, 987
Cash, S., 651
Cass, A., 344, 1083
Casserly, B., 6:E98
Cendoroglo, M., 337
Chadban, S.J., 792
Chai, W., 1060
Chan, C.T.M., 912
Chan, J.C.N., 1039
Chang, C.-S., 322
Chang, W., 850
Chavers, B.M., 166
Chen, C.-H., 322
Chen, J.-B., 6:E102
Chen, K., S2:7
Chen, T.-C., 6:E102
Cheng, B.-C., 6:E102
Cheng, C.-H., 322
Chester, K., 509
Chiang, F.-T., 720
Chien, Y.-S., 6:E102
Chin, A.I., 850
Chin, C.-Y., 720
CHOICE Study, 695
Choukroun, G., 799
Christensen, J.H., 77
Chuang, F.-R., 6:E102
Cianfrone, P., 257
Cohen, D.J., 376
Collins, A.J., 1077
Collins, D., 832
Colugnati, F.A.B., 1008
Combe, C., S2:39
Comi, N., 257
Cooke, C.R., 4:E73
Cosio, F.G., 529
Cosyns, J.-P., 2:E25
Cotter, D.J., 866
Council on Pediatric Nephrology, 1017
Craig, J.C., 591, 768
Cruess, D.F., 353
Cruz, E.A.S., 747
Cruz, J.M., 94, S2:27
Cuffe, M.S., 207
Cuppari, L., 1008
Curhan, G.C., 832
Cushman, M., 25
Cuvelier, C., 2:E25

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (August 2004) and Supplement 2 (November 2004) are preceded, respectively, by S1: and S2::

- Abbott, K.C., 353
Abe, M., 224
Acar, B., 2:E22
Adaimy, M., 636
Adler, S.G., 309
Afolabi, A., 363
Agmon, D., xlv, 6:E91
Agodoa, L.Y., 353
Ahmed, J., 498
Ahmed, M.S., 429
Akiba, T., 293, 661, 680, S2:34
Akizawa, T., 94, S2:27
Al-Absi, A.I., 4:E73
Albert, J.M., S2:34
Allon, M., 779, 859
Almpanis, C., 2:E25
Alvestrand, A., 455
Amin, M.G., 198
Amoroso, A., 987
Anderson, S., 1110
Anderstam, B., 455
Andrés, E., 4:E59
Andreucci, M., 257
Andreucci, V.E., 1024, S2:61
Angeles, C., 543
Aoki, T., 680
Ariano, R., 559
Arita, M., 112
Arjane, P., 877
Armitage, A., 121
Arons, R., 185
Arruda, J.A.L., 1031
Asakimori, Y., 112
Asano, Y., 94, S2:39
Åsberg, A., 84
Ascani, S., 757
Asif, A., 12
Atkins, R.C., 792
Attanasio, M., 611
Augustine, J.J., 1000
AusDiab Study Group, 792
Avesani, C.M., 1008
Ayanian, J.Z., 344, 1083
Aydin, Z., 179
Azap, A., 4:E47, 4:xlvii

Baccarani, M., 757
Bagnis, C.I., 1
Baigent, C., 382
Balkau, B., 792
Balletta, M.M., 1024
Bammens, B., 278
Ban, S., 902

Bárány, P., 455
Barbey, F., 799
Barbosa, D., 337
Barbour, G., 353
Barbouti, A., 286
Bardaji, A., 216
Barker, J., 859
Barth, K., 1017
Barth, R.H., 941
Barzilay, J.I., 25
Basadonna, G., 529
Bass, E.B., 695
Battaglia, M., 886
Baumelou, A., 1
Becker, B.N., 71
Belasco, A., 337
Bell, J.M., 618
Berman, E., 488
Besarab, A., 498, S2:22
Bestoso, J.T., 3:E43
Blaum, C., 25
Blazing, M.A., 207
Bleasel, K., 4:E68
Bloomfield, H., 832
Bohen, E.M., 353
Bommer, J., 94, 293, 661, S2:54
Bonner, G., xlvi, 6:E91
Borge, M.A., 429
Borgh, L., 963
Boujaoude, Z., 636
Braden, G.L., 4:E50
Bragg-Gresham, J.L., 61, 94, 293, S2:54
Bräsen, J.-H., 930
Brass, E.P., 309
Braun, N., 385
Braun, S., 627
Brewster, U.C., 5:E81
Brophy, D.F., 270
Brown, W.W., S2:22
Bruijn, J.A., 179, 773
Busque, S., 877

Cáceres-Alvarado, N., 2:E28
Caglioti, A., 257
Camargo, L., 337
Cameron, M.A., 1:E7
Canaud, B.J., S2:47
Cantarovich, F., 402
Cao, J.J., 25
Cardio-Renal Responder Group and Validation Cohort, 309
Caridi, G., 987

Cariolou, M., 300
Carr, M.E. Jr., 270
Carvalho, A.B., 747
Casari, G., 963, 987
Cash, S., 651
Cass, A., 344, 1083
Casserly, B., 6:E98
Cendoroglo, M., 337
Chadban, S.J., 792
Chai, W., 1060
Chan, C.T.M., 912
Chan, J.C.N., 1039
Chang, C.-S., 322
Chang, W., 850
Chavers, B.M., 166
Chen, C.-H., 322
Chen, J.-B., 6:E102
Chen, K., S2:7
Chen, T.-C., 6:E102
Cheng, B.-C., 6:E102
Cheng, C.-H., 322
Chester, K., 509
Chiang, F.-T., 720
Chien, Y.-S., 6:E102
Chin, A.I., 850
Chin, C.-Y., 720
CHOICE Study, 695
Choukroun, G., 799
Christensen, J.H., 77
Chuang, F.-R., 6:E102
Cianfrone, P., 257
Cohen, D.J., 376
Collins, A.J., 1077
Collins, D., 832
Colugnati, F.A.B., 1008
Combe, C., S2:39
Comi, N., 257
Cooke, C.R., 4:E73
Cosio, F.G., 529
Cosyns, J.-P., 2:E25
Cotter, D.J., 866
Council on Pediatric Nephrology, 1017
Craig, J.C., 591, 768
Cruess, D.F., 353
Cruz, E.A.S., 747
Cruz, J.M., 94, S2:27
Cuffe, M.S., 207
Cuppari, L., 1008
Curhan, G.C., 832
Cushman, M., 25
Cuvelier, C., 2:E25

- Dacouris, N., 706
 D'Agati, V.D., 376
 D'Angelo, A., 963
 Daudon, M., 799
 Davis, C.L., 529
 De Blasio, A.P., 1024
 DeLeoz, J., 651
 Della Rocca, G., 1097
 Delmonico, F.L., 529
 Dembińska-Kiec, A., 517
 Denton, M., 924
 DeOreo, P.B., S2:27
 Depner, T.A., S2:47
 Deray, G., 1
 Devries, D.T., 651
 Diamant, R., 146
 Dickinson, D.M., S2:7
 Di Paolo, S., 886
 Disney, A., S2:22
 Ditonna, P., 886
 Diven, S.C., 50
 Doline, C., 2:E15
 Donnelly, S., 715
 Donner, A., 146
 Dowling, J.K., 826
 Draibe, S., 337
 Draibe, S.A., 747, 1008
 Drey, N., 121
 Dunea, G., 1031
 Dürig, J., 556
 Dwyer, K., 551
- Egan, B.M., 446
 Eggers, P., 815
 Eisele, G., 6:E98
 Ekim, M., 2:E22
 Eknoyan, G., S2:1
 Eliasziw, M., 689
 Elisaf, M.S., 300
 Emiru, M., 941
 Ensari, A., 2:E22
 Epstein, M., 12
 Erbay, B., 2:E22, 4:E47, 4:xlvii
 Erdbruegger, U., 2:E13, 2:xlv
 Ergun, I., 4:E47, 4:xlvii
 Erturk, S., 4:E47, 4:xlvii
 Esnault, V.L.M., 402
 Ethier, J., S2:61
 Evenepoel, P., 278
- Feest, T., 121
 Feldman, J.G., 941
 Fervenza, F.C., 5:E85
 Fine, J.D., 651
 Finelli, C., 757
 Fink, N.E., 695
 Fiorenza, J., 1017
 Firkin, F., 551
 Fisher, M.E., 567
 Fissell, R.B., 293, S2:61
 Fitzgerald, J.T., 850
- Fivush, B., 1017
 Foerster, S., 840
 Fogo, A.B., 1:E1, 3:E31, 3:xlv
 Foley, R.N., 166
 Foster, K., 376
 Franger, M., 636
 Frank, R., 604
 Freeman, D.J., 689
 Friedman, A.N., 950
 Frinak, S., 498
 Frisch, G.D., 185
 Fuiano, G., 257
 Fuiano, L., 257
 Fukagawa, M., 250, 481
 Fukuhara, S., S2:54
 Fukui, H., 729
 Fukumoto, S., 250
 Furlanut, M., 1097
 Furth, S., 1017
 Fuster, D., 476
- Gadegbeku, C.A., 446
 Galaris, D., 286
 Gallego, E., 4:E59
 Gambaro, G., 963
 Gandhi, S., 912
 Gangji, A.S., 912
 Garcia, C., 216
 García-Naveiro, R., 132
 Gaston, R.S., 529
 Gauthier, B.G., 604
 Gehr, T.W.B., 270
 Gejyo, F., 250, 481
 Gelfand, E., 636
 Gerard, K., 121
 Gerson, A., 1017
 Gertz, M.A., 1103
 Ghiggeri, G.M., 987
 Gilbert, R.E., 826
 Gillen, D.L., 672
 Gillespie, B.W., 293, S2:7
 Gilmour, S.M., 4:E64
 Ginsberg, N., S2:39
 Giuliano, G.A., 385
 Glasscock, R.J., 562
 Gock, H., 551
 Goldstein, M., 706
 Goldwasser, P., 941
 Gomez, C., 4:E59
 Goodkin, D.A., 293, 661, S2:16
 Goto, N., 481, 762
 Gow, R.M., 826
 Grabensee, B., 146
 Granata, A., 5:E79, 5:xxxxix
 Grandaliano, G., 886
 Greenbaum, L.A., 604
 Greenwood, R., 121, S2:61
 Griffith, J.L., 198
 Gross, P., 840
 Grosse-Wilde, H., 556
 Gudehithlu, K.P., 1031
- Gupta, M., 363
 Gutierrez, C., 216
- Haba, T., 481, 762
 Habiba, N.M., 155
 Hadamitzky, M., 627
 Hallan, S., 84
 Hammes, J.S., 3:E43
 Haqqie, S., 6:E98
 Hara, S., 3:E38, 729
 Harada, S., 112
 Harding, G., 559
 Harris, R.C., 567
 Harris, R.Z., 1070
 Hart, P., 1031
 Hashimoto, Y., 57
 Hata, J., 437
 Heckbert, S.R., 25
 Hedayati, S.S., 207
 Heimbürger, O., 455
 Held, P.J., 94, S2:27
- Henderson, J.M., 2:E18
 Herbrig, K., 840
 Herman, A., 1090
 Herman, M., 6:E93
 Herrington, D.M., 25
 Herzog, C.A., 1077
 Hetzel, P.C., 4:E50
 High-Dose Furosemide in Acute Renal Failure Study Group, 402
 Hildebrandt, F., 611
 Hill, P., 1121
 Hill, P.A., 551
 Hirakata, H., 437
 Hirayama, A., 57
 Hirayama, K., 57
 Hisano, S., 224
 Hladik, J.A., 2:E13, 2:xlv
 Horio, T., 420
 Horiuchi, S., 224
 Hoshino, J., 3:E38
 Hosoya, T., 250
 House, A.A., 689
 Hsu, K.-T., 6:E102
 Hsu, Y.-H., 322
 Huang, J.-W., 720
 Hurwitz, S., 1050
 Hwang, W., 1017
- Ibuki, K., 328
 Iida, M., 437
 Ikeda, N., 902
 Ikeda, T., 35
 Ikemiya, Y., 642
 Illescas, L., 4:E59
 Imada, A., 729
 Inada, H., 466
 Inenaga, T., 420
 Infante, B., 886
 Inoue, T., 642
 Iseki, C., 642, 806

- Iseki, K., 642, 806
 Ishimitsu, T., 466
 Isome, M., 42, 239
 Israni, A., 488
 Itoh, K., 762
 Iwasaki, H., 224
 Iwashima, S., 328
 Iwashima, Y., 420
 Izzi, C., 987
- Jadoul, M., S2:34
 Jaffery, J.B., 71
 Janda, K., 517
 Janusz-Grzybowska, E., 517
 Jenckes, M.W., 695
 Jiang, W., 207
 Johnsen, H., 84
 Johnson, D., 488, 591
 Johnson, J.M., 155
 Johnson, L.B., 651
 Joly, D., 799
 Jonkers, I.J., 773
 Jorgetti, V., 747
 Jungers, P., 799
- Kalambokis, G.N., 575
 Kalia, A., 50
 Kamel, D., 908
 Kamide, K., 420
 Kamimura, M.A., 1008
 Kangawa, K., 420
 Kanno, Y., 902
 Karp, S.K., 344
 Kasiske, B.L., 166, 529
 Kaskel, F., 1017
 Kass, J., 636
 Kastrati, A., 627
 Kasuga, H., 328
 Katayama, A., 481, 762
 Kato, I., 437
 Katori, H., 3:E38
 Kaufman, J., 866
 Kawade, Y., 328
 Kawaguchi, Y., 729
 Kawahara, H., 328
 Kawanishi, H., 729
 Kawano, Y., 420
 Kawasaki, Y., 42, 239
 Kazama, J.J., 250, 481
 Keen, M.L., 661, S2:47
 Kelly, D.J., 826
 Kerr, P.G., 94, S2:34
 Keskanokwong, T., 64
 Kettritz, R., 930
 Kettritz, U., 930
 Keven, K., 4:E47, 4:xlvii
 Khalili, V., 1031
 Kidney and Urology Foundation of America, 1017
 Kimmel, P.L., 4:E50
 Kin, M., 729
- Kinjo, K., 642, 806
 Kirch, L., 2:E25
 Kiser, R.L., 611
 Kitano, Y., 328
 Kitiyakara, C., 815
 Kiyohara, Y., 437
 Klein, R., 25
 Klemmer, P., 611
 Klimeczek, P., 517
 Kobayashi, M., 57
 Kobayashi, S., 35
 Kobrin, S., 2:E15
 Kohno, N., 112
 Konieczynska, M., 517
 Kopp, J.B., 815
 Korzets, A., 6:E93
 Kotaki, S., 902
 Koyama, A., 57
 Kramer, H., 921
 Kribben, A., 556
 Krishnan, K.R., 207
 Kubitz, S., 1:E3
 Kubo, H., 729
 Kubo, M., 437
 Kuchibhatla, M., 207
 Kumagai, H., 35
 Kunimoto, D.Y., 4:E64
 Kurokawa, K., S2:16
 Kutlay, S., 4:E47, 4:xlvii
 Kutner, M.H., S2:7
 Kynast-Gales, S., 1060
- Lager, D., 5:E85
 Lai, F.M.M., 1039
 Lai, L.-W., 5:E85
 Lameire, N.H., S2:27
 Lamping, D., 121
 Lane, B.P., 543
 Langham, R.G., 826
 LaPorte, F.B., 446
 Larsen, J., 529
 Lazin, A., 1:E1, 1:xlv
 Le, G., 1031
 Lear, P.A., 908
 Leary, D., 1090
 Lee, C.-H., 6:E102
 Lee, C.-T., 6:E102
 Lee, J., 488
 Lee, W.-C., 322
 Leehey, D.J., 429
 Leelasa-nguan, P., 738
 Leichtman, A.B., 529
 Le Quintrec, M., 1
 Leung, N., 5:E85
 Levey, A.S., 198, 695
 Levin, N.W., S2:16
 Liberopoulos, E.N., 300
 Lieberman, M., 1060
 Lien, Y.-H. H., 5:E85
 Lima, L., 337
 Lin, J., 924
- Lindberg, M., 84
 Lindemann, M., 556
 Lindholm, B., 455
 Lipnick, R., 353
 Lipschutz, J.H., 488
 Lipschutz, J.H., 2:E15
 Litbarg, N.O., 1031
 Liu, Y.-B., 720
 Llamas, F., 4:E59
 Locatelli, F., 94, 661, S2:27
 Long-Term Peritoneal Dialysis Study Group, 729
 Lopes, A.A., S2:54
 Lopez, A., 757
 López, E., 4:E59
 López-Montes, A., 4:E59
 Lorenz, H., 402
 Lorenzo, I., 4:E59
 Lubkowski, T., 498
 Luft, F.C., 930, E3
 Lugano, M., 1097
 Lugon, J.R., 747
 Ly, J., 715
- Ma, J.Z., 1077
 MacLeod, B., 198
 Magee, C.C., 2:E18
 Majima, K., 680
 Malasit, P., 64
 Mancuso, D., 257
 Mandreoli, M., 757
 Mann, J.F.E., 627
 Mapes, D.L., S2:54
 Marashek, I., 6:E93
 Marbury, T.C., 1070
 Marcas, L., 216
 Marino, F., 257
 Markowitz, G.S., 376
 Maroni, B.J., S2:39
 Marshall, M.R., S2:47
 Marticorena, R., 715
 Martin, E.J., 270
 Martin, J.L., 611
 Martinez-Vea, A., 216
 Martirosyan, H.A., 309
 Massey, L., 1060
 Masterson, R., 4:E68
 Matsuda, M., 3:E38
 Matsuoka, H., 466
 Matsuoka, S., 481, 762
 Matsushita, K., 762
 Matuo, S., 328
 Maya, I.D., 859
 Mazza, G., 257
 McCarthy, E.T., 604
 McCarthy, J.T., S2:34
 McCullough, K.P., S2:39, S2:47
 McFarlane, P., 706
 McKevitt, P., S2:54
 McMahon, L.P., 4:E68, 509
 McVicar, J.P., 850

- Mehilli, J., 627
 Mehrotra, R., 309
 Mehta, R., 121
 Mello, P., 636
 Mendelssohn, D., 264
 Mendelssohn, D.C., 94, S2:34
 Merz, J.F., 488
 Meyer, K., 695
 Meyer, M.M., 1110
 Miller, F., 363, 543
 Miltiadous, G.A., 300
 Minami, J., 466
 Mistry, B., 4:E50
 Mitchell, R.L., 768
 Mitrogianni, Z., 286
 Mittal, B., 1050
 Mittalhenkle, A., 672
 Moe, O.W., 1:E7
 Moeckel, G., 567
 Moreiras-Plaza, M., 2:E28
 Moreno, A., 476
 Moriya, H., 35
 Mosenkis, A., 488
 Mullee, M., 121
 Murphy, C.L., 1103
 Murray, A.G., 4:E64
 Murray, B.M., 1090
 Myers, B.D., 877
- Nachamkin, I., 2:E15
 Nagase, S., 57
 Nagata, M., 57, 902
 Nair, R., 618
 Nakahama, H., 420
 Nakamoto, M., 729
 Nakamura, H., 437
 Nakamura, S., 420
 Nakanishi, S., 481
 Nangaku, M., 224
 Narva, A.S., 344
 Nathoo, B., 264
 Ndrepepa, G., 627
 Nicholson, T., 121
 Nickolas, T.L., 185
 Nihei, H., 680
 Nimmannit, S., 64
 Ninomiya, T., 437
 Nissenson, A.R., 168
 Nitta, K., 680
 Nord, E.P., 543
 Noveck, R.J., 1070
 Nozawa, R., 42, 239
 Nozawa, Y., 239
- O'Connor, C.M., 207
 Oei, L.S., 3:E33
 Oelschlaegel, U., 840
 Ohira, S., 729
 Ohta, S., 466
 Ohtake, T., 35
- Oishi, Y., 437
 Okada, H., 902
 Okubo, K., 437
 Oliver, J.A., 216
 O'Mahony, E., 6:E98
 Ono, H., 466
 Opotowsky, A.R., 185
 Ori, Y., 6:E93
 Orloff, S.L., 1110
 Ortin, J., 476
 Oser, R., 859
 Özçakar, Z.B., 2:E22
- Padhi, D., 1070
 Paemanee, A., 64
 Paganini, E.P., 1000
 Palmiero, G., 1024
 Pandeya, S., 264
 Pasowicz, M., 517
 Passauer, J., 840
 Patel, A., 429
 Patschan, D., 556
 Pauly, M., S2:61
 Pauly, R.P., 4:E64
 Pavan, F., 1097
 Pea, F., 1097
 Pellicano, R., 4:E68
 Peralta, C., 216
 Perazella, M.A., 5:E81
 Pérez, J., 4:E59
 Perez, R.V., 850
 Pérez-Fontán, M., 132
 Pérgola, P.E., 155
 Perna, A., 385
 Peteiro, J., 132
 Peters, T.G., 353
 Peterson, D., 25
 Phakdeekitcharoen, B., 738
 Philipp, T., 556
 Phillips, T.M., 4:E50
 Picken, M.M., 429
 Pifer, T.B., S2:39
 Pinkau, T., 627
 Pirulli, D., 987
 Pisoni, R.L., 22, 27, 94, S2:7
 Pistrosch, F., 840
 Plum, J., 146
 Pochet, J.M., 2:E25
 Popken, G., 930
 Port, F., 293
 Port, F.K., 47, 61, 94, 661, S2:1
 Powe, N.R., 695
 Provenzano, R., 168
 Prütz, K.-G., S2:16
- Qureshi, A.R., 455
- Raabat, R.H., 50
 Radhakrishnan, J., 185
 Rajczak, S., 1090
- Rampoldi, L., 963, 987
 Rangoonwala, B., 402
 Rao, R., 3:E33
 Ravanian, R., 908
 Rayner, D., 4:E64
 Rayner, H.C., S2:22
 Remuzzi, G., 385
 Rennke, H., 1050
 Rennke, H.G., 2:E18, 924
 Richter, E.R., 353
 Richter, S., 840
 Robins, S., 832
 Roderick, P., 121
 Rodríguez-Carmona, A., 132
 Roehrborn, A., 146
 Rogers, K.K., 488
 Roque, A., 410
 Rosenberg, M.E., 166
 Rosenblatt, I., 6:E93
 Rosenthal, D., 5:E85
 Rossini, M., 1:E1, 1:xlv, 567
 Rudnick, M., 488
 Ruhe, J., 2:E15
 Ruilope, L., 184
 Russo, D., 1024
- Saddekni, S., 859
 Sader, H., 337
 Sadler, J.H., 695
 Sahani, M., 3:E33
 Saito, A., 293, 661, S2:22
 Sakai, N., 42, 239
 Sakamoto, M., 6:E107
 Sakata, N., 224
 Sakhaei, K., 1:E7
 Salem, D.N., 198
 Salfi, M., 1070
 Sandy, D., 1000
 Santoro, A., 757
 Sapir, D., 264
 Saran, R., S2:47
 Sarnak, M.J., 198
 Satayathum, S., 661
 Sato, T., 481, 762
 Savin, V.J., 604
 Sawa, N., 3:E38
 Sawasdee, N., 64
 Sawatari, E., 762
 Saxena, A.B., 877
 Schanzler, A., 850
 Schaubel, D.E., 1083
 Schena, A., 886
 Schena, F.P., 591, 886
 Schieppati, A., 385
 Schmidt, E.B., 77
 Schmitt, R., 930
 Schneider, W., 930
 Schoenike, G., 146
 Schöning, A., 627
 Schreiber, A., 1:E3
 Schwartz, A., 6:E93

- Scolari, F., 987
 Scudeller, L., 1097
 Seifert, T.H., 1000
 Sengul, S., 4:E47, 4:xlvii
 Sequist, T.D., 344, 1083
 Serrano, A., 4:E59
 Sessa, A., 5:E79, 5:xxxix
 Sesso, R., 337, 410
 Sethi, S., 3:E33
 Shang, S., 5:E85
 Sharma, A., 3:E43
 Sharma, M., 604
 Shaw, J.E., 792
 Shey, J., 1:E7
 Shigematsu, T., 250
 Shigemoto, K., 112
 Shimizu, Y., 57
 Shoji, T., 729
 Shryayef, M.Z., 446
 Shroff, G.R., 1077
 Shu, K.-H., 322
 Siamopoulos, K.C., 300
 Siampoulos, K.C., 286
 Silbert, S., 337
 Silverman, J.A., 912
 Simmons, E., 567
 Singh, A., 1031
 Singh, A.K., 1050
 Snyder, R.W., 2:E14, 488
 Solomon, A., 1103
 Somerville, C., 1121
 Spence, J.D., 689
 Sritippayawan, S., 64
 Sølling, J., 77
 Stallone, G., 886
 Stark, P.C., 198
 Stefanik, K., 866
 Stehman-Breen, C.O., 672
 Stein, A., 651
 Steinberg, D., 1116
 Steinberger, J., 937
 Stella, S., 410
 Stenvinkel, P., 455
 Stiles, S.K., 344
 Stompór, T.P., 517
 Strippoli, G.F.M., 591
 Suchindran, C., 651
 Sugahara, S., 902
 Sukolsky, A., 893
 Suliman, M.E., 455
 Sullivan, J.T., 1070
 Sumboonnanonda, A., 64
 Sułowicz, W., 517
 Suzuki, H., 6:E107, 42, 239, 902
 Suzuki, J., 42, 239
 Suzuki, K., 680
 Svensson, M., 77
 Swan, S.K., 166
 Swanson, S.J., 353
 Szczecz, L.A., 207
- Tagami, T., 3:E38
 Takahashi, H., 328
 Takaichi, K., 3:E38
 Takami, Y., 420
 Takane, H., 902
 Takasugi, N., 112
 Takemoto, F., 3:E38
 Takenaka, T., 6:E107
 Takishita, S., 642, 806
 Takiuchi, S., 420
 Tam, P., 264
 Tan, J.C., 877
 Tanaka, J., 112
 Tanaka, K., 437
 Tanaka, M., 762
 Tang, M.-J., 322
 Tanizaki, Y., 437
 Tanji, M., 42
 Tannji, M., 239
 Tapp, R.J., 792
 Tardanico, R., 987
 Taylor, E.N., 2:E18
 Teutonico, A., 886
 Textor, S.C., 369
 Thamer, M., 866
 Thomas, D.B., 2:E13, 2:xlv
 Thomson, N.M., 826
 Thornton, M.J., 908
 Thuwajit, P., 64
 Tighiouart, H., 198
 Timm, E.G., 6:E98
 Ting, R., 264
 Tintillier, M., 2:E25
 Tominaga, Y., 481, 762
 Tomlinson, B., 1039
 Tomson, C.R.V., 908
 Tonelli, M., 832
 Tong, A., 591
 Tong, P.C.Y., 1039
 Tonkin, A.M., 792
 Toriyama, T., 328
 Torregrosa, J.V., 476
 Townsend, J., 121
 Trachtman, H., 604
 Tracy, R.P., 25
 Tracz, W., 517
 Travis, L.B., 50
 Troppmann, C., 850
 Tsatsoulis, A.A., 575
 Tselepis, A.D., 300
 Tsianos, E.V., 575
 Tsukada, K., 466
 Tulunay, Ö., 2:E22
- Ubara, Y., 3:E38
 Uchida, K., 481, 680, 762
 Ueki, T., 481, 762
 Uesugi, N., 224
 Urizar, R., 6:E98
 Urology of New York/New Jersey,
 1017
- Urquhart, B.L., 689
 Usui, J., 57
 Usui, K., 112
 Valveny, N., 476
 Vanherweghem, J.L., 1
 Vanrenterghem, Y., 278
 Vasuvattakul, S., 64
 Verbeke, K., 278
 Verho, M., 402
 Vernik, J., 1031
 Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators, 832
 Vezzoli, G., 963
 Viale, P., 1097
 Vianelli, N., 757
 Vianna, L., 337
 Viciso, B., 410
 Villaverde, P., 132
 Vleming, L.J., 179
 Vleming, L.-J., 773
- Wadgymar, A., 264
 Wadhwa, N.K., 363
 Wagner, A., 840
 Walker, P.D., 618
 Walker, R.G., 509
 Wall, B.M., 4:E73
 Wang, P.-L., 1110
 Wang, S., 1103
 Wang, Y., 3:E31, 3:xlv
 Warady, B., 604
 Warnock, D.G., 369
 Wasserstein, A., 2:E15
 Watanabe, M., 328
 Watanabe, R.I., 680
 Watanabe, Y., 902
 Weale, A.R., 908
 Weaver, K., 1103
 Webster, A.C., 768
 Weiner, D.E., 198
 Weiner, M., 651
 Weisberg, L.S., 636
 Weiss, D.T., 1103
 Weiss, L., 1017
 Welborn, T.A., 792
 Wenzel, R.R., 556
 Wheeler, D.C., 917
 Wichmann, G., 840
 Wikström, B., S2:54
 Wilairat, P., 64
 Wills, S., 695
 Windrim, R., 912
 Witzke, O., 556
 Wizermann, V., S2:61
 Wójcik, K., 517
 Wolf, M.T.F., 611
 Wolfe, R.A., S2:7
 Wolpe, P.R., 488
 Wong, G., 264

- Wong, W., 924
 Wu, G., 264
 Wu, K.-D., 720
 Wu, M.-J., 322
 Wu, M.-S., 720
 Wu, V.-C., 720
 Yalçinkaya, F., 2:E22
 Yamagata, K., 57
 Yamashita, K., 112
 Yamashita, T., 250, 481
 Yang, C.-C., 6:E102
 Yassa, T., 706
 Yasuda, K., 328
 Ybarra, J., 476
 Yeates, K.E., 1083
 Yenchitsomanus, P., 64
 Yoh, K., 57
 Yorioka, N., 112
 Yoshihara, F., 420
 Young, E.W., 34, 94, 293, 661, S2:16
 Yüksel, S., 2:E22
 Zalewski, I., 611
 Zamboli, P., 257
 Zamora, J., 385
 Zdienicka, A., 517
 Zelenitsky, S., 559
 Zelikovsky, N., 1017
 Zent, R., 567
 Zhang, Y., 826, 866
 Zhao, H.-L., 1039
 Zimmet, P.Z., 792
 Zohar, M., xlv, 6:E91

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (August 2004) and Supplement 2 (November 2004) are preceded, respectively, by S1: and S2::

- Acceptability, of HD in renal satellite units in England and Wales, 121–131
 Access, vascular. *See* Vascular access
 Access to care
 of hemodialysis in renal satellite units in England and Wales, 121–131
 renal transplantation among American Indians and Hispanics, 334–352
 ACE deletion allele polymorphism, cardiovascular risk and, 466–476
 ACE inhibitors. *See* Angiotensin-converting enzyme inhibitors
N-Acetylcysteine, for radiocontrast-induced nephropathy prophylaxis, 12–24
 Acidosis, effect of predialysis serum bicarbonate on mortality and hospitalization risks, 661–671
 Acquired cystic kidney disease, xanthogranulomatous pyelonephritis in anephric patient, 930–936
 Acute renal failure (ARF)
 and cerebral infarcts in young woman, 179
 chronic crystal-forming interstitial nephritis, tosufloxacin tosilate and, 902–907
 herbal therapy and, 1–11
 high-dose furosemide for, 402–409
 hospital-acquired, radiocontrast-induced, prophylaxis for, 12–24
 in hospitalized elderly, prognosis for, 410–419
 intermittent versus continuous dialysis for, 1000–1007
 mortality, in inherited epidermolysis bullosa, 651–660
 in propofol infusion syndrome, 6:E98
 transjugular renal biopsy and hemodialysis catheter placement in, 429–436
 Acute tubular necrosis risk, from herbal therapy, 1–11
 Adequacy, of peritoneal dialysis, 2:S36–40
 Adherence to treatment, religiosity in hemodialysis population and, 488–497
 Adolescents with anemia of chronic kidney disease, health-related quality of life of, 1017–1023
 Adrenal ganglioneuroma, with membranoproliferative glomerulonephritis, 363–368
 Advanced glycation end products, medial smooth muscle cell injury in diabetic nephropathy and, 224–238
 African Americans, ESRD from focal segmental glomerulosclerosis in, 815–825
 Aging
 cardiovascular risk factor relationship with microalbuminuria and, 25–34
 renal biopsy abnormalities and, 618–626
 Albumin, serum
 adult in-center hemodialysis patients and, 2:S18–36
 effect of hemodialysis modality on plasma fibrinogen level, 941–949
 mortality risk and, 2:S14–15
 pediatric patients in-center hemodialysis and, 2:S51
 peritoneal dialysis patients and, 2:S40–44
 Albumin, urinary. *See* Microalbuminuria
 Aldosteronism, calcium nephrolithiasis associated with, 1:E7
 Alkylating agents, immunosuppression for idiopathic membranous nephropathy and, 385–401
 Allograft dysfunction, reversible, fenofibrate-associated, 543–550
 Allograft nephropathy, C₂ monitoring of cyclosporine A exposure and, 886–892
 American Indians, access to renal transplantation, 334–352
 Amino acids, inflammation and mortality in CKD patients starting hemodialysis, 455–465
 Amyloidosis
 in inherited epidermolysis bullosa, renal disease mortality and, 651–660
 with novel mutant Leu64Pro, 1103–1109
 ANCA. *See* Antineutrophil cytoplasmic antibodies

- Anemia
 epoetin requirements in predicting mortality in HD, 866–876
 HRQL in adolescents with chronic kidney disease and, 1017–1023
 management
 of in-center hemodialysis pediatric patients, 2:S48–50
 and outcome in 12 countries, 94–111
 in peritoneal dialysis, 2:S40–44
 red blood cell survival in chronic renal failure, 715–719
 Angioplasty, vascular access stenosis in arteriovenous grafts versus fistulas, 859–865
 Angiotensin-converting enzyme deletion allele polymorphism, cardiovascular risk and, 466–476
 Angiotensin-converting enzyme inhibitors
 in IgA nephropathy, exercise and, 257–263
 potassium in CAPD patients and, 738–746
 Angiotensin receptor blockers, potassium in CAPD patients and, 738–746
 Anion exchanger protein
 monogenic renal calcium-stone disorders and, 963–986
SLC4A1 mutations in autosomal recessive distal renal tubular acidosis and, 64–70
 Anterior ischemic optic neuropathy, in calcific uremic arteriopathy, 6:E93
 Antibiotics
 for dialysis-catheter related bacteremia, 779–791
 empiric therapy for peritoneal dialysis-related peritonitis, 559–561
 expanded-spectrum β -lactamase producing *Klebsiella pneumoniae*-related peritonitis, 6:E102
 hypotension unmasked by β -lactamase during dextran sulfate LDL apheresis and, 6:E107
 in peritoneal dialysis-related peritonitis prevention, 591
 Anticoagulation
 immobilization hypercalcemia and bone resorption in CRRT, 1110–1114
 serum concentrations, effect of dialysis membranes on, 509–516
 Anti-EPO antibody levels, in chronic kidney disease after epoetin alfa therapy, 264–269
 Antifactor Xa
 enoxaparin anticoagulant activity in ESRD and, 270–277
 serum concentrations, effect of dialysis membranes on, 509–516
 Antigen presentation, lack of monocytes in pulmonary renal syndrome and, 556–558
 Antineutrophil cytoplasmic antibodies (ANCA)
 polyangiitis syndrome, hemoperitoneum in, 908–911
 renal vasculitis, mizoribine for, 57–63
 Antioxidants, for radiocontrast-induced nephropathy prophylaxis, 12–24
 Antiphospholipid syndrome, acute renal failure and cerebral infarcts in, 179
 Anti-rHuEPO antibodies, resumption of epoetin alfa after rituximab therapy for pure red cell aplasia, 757–761
 ApoE polymorphism, serum lipids in hemodialysis patients and, 300–308
 Apolipoprotein A-I amyloidosis, with novel mutant Leu64Pro, 1103–1109
 Apolipoprotein E, serum lipids in hemodialysis patients and, 300–308
 Aquaporin 1, peritoneal distribution/expression in PD patients, 146–154
 ARF. See Acute renal failure
 Aristolochic acid-associated nephropathy, herbal therapy and, 1–11
 Arrhythmias
 ventricular, during and after hemodialysis, coronary stenosis and, 328–336
 Arrhythmias, effect of iron stores on QT_c dispersion in PD patients, 720–728
 Arteriosclerosis, coronary artery calcification scores during PD, 517–528
 Arteriovenous fistula (AVF)
 intra-access blood flow in, 850–858
 surgical banding effects on, 1090–1096
 vascular access stenosis and, 859–865
 Ascorbic acid, oxalate absorption and endogenous synthesis from, 1060–1069
 Asia *bogorensis* peritonitis, identified by 16S ribosomal RNA sequence analysis, 2:E15
 Atazanavir, acute interstitial nephritis associated with, 5:E81
 Atkins weight-loss diet, effects on kidney and kidney disease, 950–962
 Autoinfarction, spontaneous mediastinal parathyroid autoinfarction after parathyroidectomy, 762–767
 Autologous stem cell transplantation, for light chain deposition disease, 551–555
 Automated peritoneal dialysis, versus continuous ambulatory peritoneal dialysis, 132–145
 Autosomal dominant medullary cystic kidney disease, type I in large Native-American kindred, 611–617
 Autosomal dominant polycystic kidney disease, exercise blood pressure, cardiac structure and diastolic function in normotensive patients, 216–223
 Autosomal recessive distal renal tubular acidosis, *SLC4A1* mutations in, 64–70
 AVF. See Arteriovenous fistula
 Bacteremia, dialysis-catheter related bacteremia, 779–791
 Bacterial endocarditis, long-term survival in dialysis patients and, 1077–1082
 Baroreflex impairment, in chronic kidney disease and, 446–454
 Beck Depression Inventory, evaluation of depression mortality risk in CKD with heart failure, 207–215
 Behavior, dialysis staff problems in dealing with difficult patients, 893–901
 β -lactamase
 expanded-spectrum, producing *Klebsiella pneumoniae*-related peritonitis, 6:E102
 hypotension during dextran sulfate LDL apheresis and, 6:E107
 Bicarbonate, predialysis levels and risk of mortality and hospitalization, 661–671
 Biofilms, xanthogranulomatous pyelonephritis in anephric patient, 930–936
 Biopsies, aquaporin 1 distribution/expression in peritoneum of PD patients, 146–154

- Blood flow
dialyzer delivered, effect of blood tubing sets on, 498–508
intra-access
surgical banding of AVF and, 1090–1096
in under-arm native AVF, 850–858
- Blood pressure. *See also* Hypertension
APD versus CAPD effects on, 132–145
in CRF, effect of n-3 PUFA on, 77–83
during exercise in normotensive ADPKD patients, 216–223
hypotension, AION in calcific uremic arteriolopathy and, 6:E93
- Blood temperature monitoring, during hemodialysis, 155–165
- Blood tubing sets, influence on delivered dialyzer blood flow, 498–508
- Body temperature regulation, during hemodialysis, 155–165
- Bone disease
histologic patterns after kidney transplantation, 747–756
mortality risk in dialysis patients with hip fracture, 672–679
- Bone mineral density
cyclic intermittent etidronate effect on coronary artery calcification in HD, 680–688
monogenic renal calcium-stone disorders and, 963–986
- Bone resorption, with prolonged anticoagulation in CRRT, 1110–1114
- Botanical medicine, renal hazards from, 1–11
- Bradykinin, unmasking of hypotension by β -lactam during dextran sulfate LDL apheresis, 6:E107
- Brain natriuretic peptide, diagnostic/prognostic in CRF, 420–428
- Breast cancer patient, on immunosuppressive therapy with crescentic glomerulonephritis and dense deposit disease, 3:E33
- Breathing, sleep-disordered, proteinuria and, 636–641
- Calcific uremic arteriolopathy, ischemic optic neuropathy in, 6:E93
- Calcinosis cutis, traumatic in dialysis patient, 2:E18
- Calcitrol, intravenous, MIBI scintigraphy in predicting treatment response, 476–480
- Calcium nephrolithiasis
associated with primary aldosteronism, 1:E7
genetics of, 963–986
- Calcium-phosphate balance, coronary artery calcification scores during peritoneal dialysis, 517–528
- Calcium-sensing receptor, monogenic renal calcium stone disorders and, 963–986
- Calcium stones
end-stage renal disease and, 799–805
monogenic renal disorders with, 963–986
- Calibration, of MDRD formula for estimating glomerular filtration rate, 84–93
- CAPD. *See* Continuous ambulatory peritoneal dialysis
- Capillary permeability, of insulin-treated diabetics, 575–590
- Carbohydrates, low with high-protein diets, effects on kidney and kidney disease, 950–962
- Carboxymethyllysine, medial smooth muscle cell injury in diabetic nephropathy and, 224–238
- Cardiac output, surgical banding of arteriovenous fistula and, 1090–1096
- Cardiologists, cardiovascular disease management in ESRD, 309–321
- Cardiopulmonary congestion, insulin-induced, 575–590
- Cardiovascular disease
in CRF, effect of n-3 PUFA supplements on, 77–83
dimercaptosuccinic acid for hyperhomocysteinemias in hemodialysis, 689–694
in ESRD, management by nephrologists versus cardiologists, 309–321
late urinary tract infection after renal transplantation, 353–362
in men with chronic renal insufficiency, effect of gemfibrozil on renal function in, 832–839
morbidity/mortality, APD versus CAPD, 132–145
in nondiabetic hemodialysis patients, ENOS gene polymorphisms and, 112–120
recurrent, kidney disease as risk factor for, 198–206
renal insufficiency and, 627–635
risk
cross-association with microalbuminuria and, 25–34
deletion allele of ACE gene polymorphism and, 466–476
- Cardiovascular Health Study, relationship of cardiovascular risk factors with microalbuminuria in older adults, 25–34
- Catheters
hemodialysis
bacteremia-related to, treatment and prophylaxis for, 779–791
placement in ARF, transjugular renal biopsy and, 429–436
tunneled, squamous cell carcinoma in situ at exit site of, 3:43
- peritoneal dialysis, obstruction caused by fallopian tube wrapping, 2:E28
- CCPD (continuous cycling peritoneal dialysis), patients' preferences in choice of dialysis modality and dose, 695–705
- Cerebral infarcts
and ARF in antiphospholipid syndrome, 179
in chronic kidney disease, 35–41
- Children. *See* Pediatric patients
- Chronic kidney disease (CKD)
access to renal transplantation for American Indians and Hispanics, 334–352
adolescents with anemia, health-related quality of life and, 1017–1023
 α_1 -adrenoreceptor pressor sensitivity, lipid enhancement of, 446–454
asymptomatic cerebral lacunae in, 35–41
awareness in U.S. population, 185–197
cinacalcet pharmacokinetics, pharmacodynamics and safety in, 1070–1076
coronary artery calcification in, 1024–1030
depression mortality risk with congestive heart failure and, 207–215
development, hyperhomocysteinemias and, 437–445
with diabetes mellitus, transplantation in, 529–542

- diagnostic and prognostic value of brain natriuretic peptide in, 420–428
- effect of n-3 PUFA supplements on plasma lipids, lipoproteins and blood pressure in, 77–83
- end-stage renal disease risk, low GFR, proteinuria and, 806–814
- evaluation of eHealth web sites for, 71–76
- hemodialysis patients, apoE and serum lipids in, 300–308
- late urinary tract infection after renal transplantation, 353–362
- in men
- with coronary disease, gemfibrozil effect on renal function in, 832–839
 - elderly with membranoproliferative glomerulonephritis, 1121–1125
- mortality, hyperhomocysteinemia in relation to free amino acids and inflammation, 455–465
- progression, lipid-lowering therapy and, 917–920
- red blood cell survival in, 715–719
- resting energy expenditure in, 1008–1016
- resumption of epoetin alfa after rituximab treatment for pure red cell aplasia, 757–761
- as risk factor for recurrent cardiovascular disease/mortality, 198–206
- Cinacalcet, pharmacokinetics/pharmacodynamics of, 1070–1076
- Circulating immune complexes, in mitomycin C-induced hemolytic uremic syndrome, 4:E50
- Citrate anticoagulation, immobilization hypercalcemia and bone resorption in CRRT, 1110–1114
- CKD. *See* Chronic kidney disease
- Classification, of lupus nephritis subclasses, 1050–1059
- Clearance
- effect of blood tubing sets on delivered dialyzer blood flow, 498–508
 - in pediatric patients in-center hemodialysis, 2:S45
- Clinical nephrology practice, economics of, 168–178
- Clinical trials. *See* Randomized controlled trials; specific clinical trials
- Clot elastic modulus, enoxaparin anticoagulant activity in ESRD and, 270–277
- Cochrane Renal Group Report, systematic reviews related to kidney disease, 768–772
- Collapsing focal segmental glomerulosclerosis, interferon alfa for hepatitis C with nephrotic syndrome and, 567–573
- Colonic transit time, in long-term dialysis patients, 322–327
- CombiSet blood tubing set, effect on delivered dialyzer blood flow, 498–508
- Community-acquired acute renal failure in elderly, prognosis for, 410–419
- Community-dwelling adults, hyperhomocysteinemia and CKD development in, 437–445
- Complex disease, monogenic renal calcium stone disorders and, 963–986
- Congestive heart failure
- with chronic kidney disease, depression mortality risk and, 207–215
 - effect of surgical banding on access flow and cardiac output, 1090–1096
- Constipation, colonic transit time in long-term dialysis, 322–327
- Continuous ambulatory peritoneal dialysis (CAPD)
- effects of ACE inhibitors or angiotensin receptor blockers on potassium, 738–746
 - expanded-spectrum β -lactamase producing *Klebsiella pneumoniae*-related peritonitis, 6:E102
 - patients' preferences in choice of dialysis modality and dose, 695–705
 - versus automated peritoneal dialysis, 132–145
- Continuous cycling peritoneal dialysis (CCPD), patients' preferences in choice of dialysis modality and dose, 695–705
- Continuous hemodialysis, versus intermittent for acute renal failure, 1000–1007
- Continuous renal replacement therapy (CRRT)
- bone resorption and "relative" immobilization hypercalcemia with prolonged anticoagulation, 1110–1114
 - red blood cell survival in chronic renal failure, 715–719
 - versus intermittent dialysis for acute renal failure, 1000–1007
- Continuous venovenous hemofiltration (CVVH)
- linezolid deposition after standard dose in critically ill patients, 1097–1102
 - for radiocontrast-induced nephropathy prophylaxis, 12–24
- Convective transport, for removal of protein-bound solute p-cresol, 278–285
- Core curriculum in nephrology
- economics of clinical nephropathy practice, 168–178
 - hypertension, 369–374
- Coronary angiography, coronary stenosis and ventricular arrhythmias in hemodialysis, 328–336
- Coronary angioplasty, cardiovascular outcomes in renal insufficiency patients, 627–635
- Coronary artery calcification
- in chronic renal failure patients not undergoing dialysis, 1024–1030
 - effects of cyclic intermittent etidronate therapy on, 680–688
 - progression during peritoneal dialysis, inflammation and, 517–528
- Coronary heart disease. *See* Cardiovascular disease
- Coronary stenosis, ventricular arrhythmias during and after hemodialysis and, 328–336
- Cost evaluation, of hemodialysis in renal satellite units in England and Wales, 121–131
- C-reactive protein (CRP)
- relationship to microalbuminuria, 25–34
 - resting energy expenditure in chronic kidney disease, 1008–1016
- Creatinine, serum
- late urinary tract infection after renal transplantation, 353–362
- MDRD formula for estimating glomerular filtration rate and, 84–93
- in radiocontrast-induced nephropathy, 12–24
 - screening for kidney disease in diabetic adults, 921–923
- Creatinine clearance
- coronary revascularization in renal insufficiency patients, 627–635

- predicted, proteinuria and ESRD risk, 806–814
resting energy expenditure in chronic kidney disease, 1008–1016
- Crescentic glomerulonephritis, and dense deposit disease in breast cancer patient on immunosuppressive therapy, 3:E33
- Crescents, glomerular, in lupus nephritis subclasses, 1050–1059
- CRRT. *See* Continuous renal replacement therapy
- Cryoglobulinemia, with renal insufficiency, proteinuria, hematuria, hemiparesis and pleuritis, 1121–1125
- Crystal-forming chronic interstitial nephritis, tosufloxacin tosilate and, 902–907
- Cyclosporine A
C₂ monitoring, long-term graft function and, 886–892
for recurrent pediatric focal segmental glomerulosclerosis, 50–56
- Cysteine, mortality of CKD patients starting hemodialysis and, 455–465
- Cystic kidney disease, clinical aspects and mechanisms of, 987–999
- Cytomegalovirus, late urinary tract infection after renal transplantation, 353–362
- Darbepoetin alfa, effect of dialysis membranes on serum concentrations during dialysis, 509–516
- Death. *See* Mortality
- Dense deposit disease, and crescentic glomerulonephritis in breast cancer patient on immunosuppressive therapy, 3:E33
- Dent's disease, genetics of, 963–986
- Depression, chronic kidney disease and mortality in congestive heart failure and, 207–215
- Desmopressin acetate, hyponatremia induced by, 1:E3
- Dextran sulfate LDL apheresis, unmasking of hypotension by β -lactam during, 6:E107
- Diabetes mellitus
with chronic kidney disease, transplantation in, 529–542
early stages, albuminuria in, 792–798
relationship of cardiovascular risk factors with microalbuminuria, 25–34
screening for kidney disease in adults, 921–923
type II, nodular glomerulosclerosis in, 1039–1049
vascular complications in, 575–590
- Diabetic nephropathy
albuminuria in early stages of diabetes mellitus, 792–798
mechanism of medial smooth muscle cell injury in, 224–238
nodular glomerulosclerosis and, 1039–1049
urotensin II and urotensin II receptor expression in, 826–831
- Dialysate temperature, during hemodialysis, 155–165
- Dialysis. *See also* specific dialysis modalities
adolescents with anemia of CKD, health-related quality of life and, 1017–1023
- ESRD from focal segmental glomerulosclerosis and, 815–825
increased risk of mortality with hip fracture, 672–679
long-term survival, bacterial endocarditis and, 1077–1082
traumatic calcinosis cutis in, 2:E18
- Dialysis dose, patients' preferences in choice of dialysis modality and, 695–705
- Dialysis membrane, high-flux versus low-flux effects on anticoagulation during dialysis, 509–516
- Dialysis modalities. *See also* specific dialysis modalities
effect on plasma fibrinogen, 941–949
patients' preferences in choices between, 695–705
- Dialysis Outcomes and Practice Patterns Study (DOPPS)
anemia management and outcomes in 12 countries, 94–111
international variation in vitamin prescription, mortality and, 293–299
predialysis serum bicarbonate levels, mortality and hospitalization risk, 661–671
- Diastolic function, in young normotensive ADPKD patients, 216–223
- 1,25-Dihydroxyvitamin D₃, fibroblast growth factor-23 in secondary hyperparathyroidism and, 250–256
- Dimercaptosuccinic acid, for hyperhomocysteinemia in hemodialysis patients, 689–694
- Disruptive behavior, dialysis staff problems in dealing with difficult patients and, 893–901
- Distal renal tubular acidosis, autosomal recessive, SLC4A1 mutations in, 64–70
- Donor, kidney
living
medullary cystic kidney disease type I in Native-American kindred and, 611–617
preoperative renal volumes in predicting graft function, 877–885
paired exchange, unfairness of, 1115–1120
severe sepsis in, 4:E64
transplantation in face of severe sepsis, 4:E64
- Donor waiting list, unfairness of paired kidney exchange and, 1115–1120
- DOPPS. *See* Dialysis Outcomes and Practice Patterns Study
- Echocardiogram, for cardiovascular disease in ESRD, management by nephrologists versus cardiologists, 309–321
- Economics
of clinical nephropathy practice, core curriculum for, 168–178
cost evaluation of HD in renal satellite units, 121–131
- Ectopic gland, spontaneous mediastinal parathyroid autoinfarction after parathyroidectomy, 762–767
- Edema, insulin and, 575–590
- eHealth web sites, evaluation for chronic kidney disease patients, 71–76
- Elderly
with hospital-acquired versus community-acquired acute renal failure, prognosis for, 410–419
relationship of cardiovascular risk factors with microalbuminuria in older adults, 25–34
renal biopsy abnormalities in, 618–626
- Empiric therapy, for peritoneal dialysis-related peritonitis, 559–561
- Encapsulating peritoneal sclerosis, in Japan, 729–737
- Endothelial cells, glomerular injury, FB21 as marker for, 239–249

- Endothelial nitric oxide synthase gene polymorphism, cardiovascular events in nondiabetic HD patients and, 112–120
- Endothelial progenitor cells, in long-term hemodialysis, 840–849
- Endothelium-derived hyperpolarizing factor, unmasking of hypotension by β -lactam during dextran sulfate–LDL apheresis, 6:E107
- End-stage renal disease (ESRD) in Canadian minorities, access to renal transplantation for, 1083–1089
- cardiovascular disease management by nephrologists versus cardiologists, 309–321
- cardiovascular risk, deletion allele of ACE polymorphism and, 466–476
- enoxaparin enhanced anticoagulant activity in, 270–277
- expanded-spectrum β -lactamase producing *Klebsiella pneumoniae*-related peritonitis in PD patient, 6:E102
- from focal segmental glomerulosclerosis, increased incidence of, 815–825
- Medicare program, 2:S11
- nephrolithiasis-related, 799–805
- peritoneal dialysis-related peritonitis, antimicrobial prevention of, 591
- pregnancy with nocturnal hemodialysis, 912–916
- risk, hyperuricemia and, 642–650
- risk, low GFR, proteinuria and, 806–814
- staff problems in dealing with difficult patients, 893–901
- ENOS* polymorphism, cardiovascular events in nondiabetic HD patients and, 112–120
- Enoxaparin effect of dialysis membranes on serum concentrations during dialysis, 509–516
- enhanced anticoagulant activity in ESRD, 270–277
- Epidermolysis bullosa, inherited, renal disease mortality and, 651–660
- Erythropoietin for anemia management of HD patients, international variations in, 94–111
- anti-EPO antibody levels in CRF patients, 264–269
- dose requirements, mortality in hemodialysis patients and, 866–876
- effect of dialysis membranes on serum concentrations during dialysis, 509–516
- responsiveness, mortality in hemodialysis and, 866–876
- resumption after rituximab therapy for pure red cell aplasia, 757–761
- E-selectin, in hemolytic uremic syndrome and Henoch-Schönlein purpura nephritis, 238–249
- ESRD. *See* End-stage renal disease
- ESRD Clinical Performance Measures Project, 2003 Annual Report, 2:S3–2:S92
- Ethics, paired exchange for kidney transplantation, 1115–1120
- Ethnicity, kidney disease awareness and, 185–197
- Etidronate, cyclic intermittent, effect on coronary artery calcification in hemodialysis patients, 680–688
- Exercise blood pressure, in young normotensive ADPKD patients, 216–223
- Exit-site and tunnel infection, antibiotic prevention of peritoneal dialysis-related peritonitis, 591
- Expanded-spectrum β -lactamase, producing *Klebsiella pneumoniae*-related peritonitis, 6:E102
- Extracellular matrix, in nodular glomerulosclerosis with diabetes, 1039–1049
- Fabry disease, renal variant, α -galactosidase A mutant in, 5:E85
- Familial hyperuricemic nephropathy, clinical aspects and mechanisms of, 987–999
- Family genetic linkage analysis, medullary cystic kidney disease type I in Native-American kindred and, 611–617
- Fatty acids, n-3-polyunsaturated, effect on plasma lipids, lipoproteins and blood pressure in CRF, 77–83
- FB21, as marker for glomerular endothelial cell injury, 239–249
- Fenofibrate nephrotoxicity, in renal transplant recipients, 543–550
- Fenoldopam, for radiocontrast-induced nephropathy prophylaxis, 12–24
- Fibrin acid derivative, effect on renal function in men with CKD and coronary disease, 832–839
- Fibrinogen asymptomatic cerebral lacunae in chronic kidney disease and, 35–41
- dialysis modality effect on, 941–949
- Fibroblast growth factor-23 (FGF-23)
- secondary hyperparathyroidism with renal insufficiency and, 250–256
- total parathyroidectomy for secondary hyperparathyroidism and, 481–487
- Fistula banding, effect on access flow and cardiac output, 1090–1096
- Flomoxef, producing *Klebsiella pneumoniae*-related peritonitis in PD patient, 6:E102
- Fluid transport, aquaporin 1 distribution/expression in peritoneum of PD patients and, 146–154
- Focal segmental glomerulosclerosis
- ESRD from, increased incidence of, 815–825
- recurrent pediatric, high-dose oral cyclosporin therapy for, 50–56
- Folate, in hemodialysis patients, mortality/hospitalization and, 293–299
- Furosemide, for acute renal failure, 402–409
- α -Galactosidase A mutant, in renal variant of Fabry disease, 5:E85
- Gemfibrozil, effect on renal function in men with CKD and coronary disease, 832–839
- Genetics. *See also* Mutations; Polymorphisms
- of hypercalcemia and calcium nephrolithiasis, 963–986
- Glomerular endothelial cell injury, FB21 as marker for, 239–249
- Glomerular filtration rate
- high-protein diets and, 950–962
- hyperhomocysteinemia, chronic kidney disease development and, 437–445
- MDRF formula for estimating, validation of, 84–93
- Glomerular permeability activity, in children with idiopathic nephrotic syndrome, 604–610
- Glomerulocystic kidney disease, clinical aspects and mechanisms of, 987–999

- Glomerulonephritis. *See also* Crescentic glomerulonephritis; Membranoproliferative glomerulonephritis
diagnosis by renal biopsy in elderly patients, 618–626
IgG subclass deposition in children, 42–49
in inherited epidermolysis bullosa, renal disease mortality and, 651–660
Glomerulosclerosis, focal segmental. *See* Focal segmental glomerulosclerosis
Glucose tolerance, albuminuria in early stages of diabetes mellitus, 792–798
Glycoxidation-mediated local complement activation, medial smooth muscle cell injury in diabetic nephropathy and, 224–238
Gout, hyperuricemia as ESRD risk factor, 642–650
Gracz fistula, intra-access blood flow in, 850–858
Grafts
 allograft nephropathy, C₂ monitoring of cyclosporine A exposure and, 886–892
 dysfunction, reversible, fenofibrate-associated, 543–550
 long-term function, C₂ monitoring of cyclosporine A exposure and, 886–892
 loss, late urinary tract infection after renal transplantation, 353–362
 prediction of function, preoperative renal volumes in living donor transplants, 877–885
 vascular access stenosis and, 859–865
- Haplotype analysis, of medullary cystic kidney disease type I in Native-American kindred, 611–617
- HCV infection. *See* Hepatitis C infection
- HD. *See* Hemodialysis
- Health on the Net Foundation Code of Conduct, evaluation of eHealth web sites for chronic kidney disease patients, 71–76
- Health-related quality of life, in adolescents with chronic kidney disease, anemia and, 1017–1023
- Heart failure, in chronic renal failure, brain natriuretic peptide and, 420–428
- Hematocrit
 epoetin requirements in predicting mortality in hemodialysis, 866–876
 health-related quality of life in adolescents with chronic kidney disease and, 1017–1023
- Hematuria, in elderly man with membranoproliferative glomerulonephritis, 1121–1125
- Hemiparesis, in elderly man with membranoproliferative glomerulonephritis, 1121–1125
- Hemodialfiltration, removal of protein-bound solute p-cresol, 278–285
- Hemodialysis (HD). *See also* Nocturnal hemodialysis; Vascular access
 apolipoprotein E, lipids levels and, 300–308
 body temperature regulation during, 155–165
 cardiovascular events in nondiabetic patients, ENOS polymorphism and, 112–120
 catheter. *See* Catheters, hemodialysis
 chronic kidney disease mortality, hyperhomocysteinemia, free amino acids, inflammation and, 455–465
 clinical and cost evaluation in renal satellite units in England and Wales, 121–131
- dialyzer delivered blood flow, effect of blood tubing sets on, 498–508
- Dimercaptosuccinic acid for hyperhomocysteinemia in, 689–694
- effect on plasma fibrinogen level, 941–949
- high-flow fistula, effect of surgical banding on access flow and cardiac output, 1090–1096
- intermittent versus continuous for acute renal failure, 1000–1007
- ischemic optic neuropathy in calcific uremic arteriolopathy, 6:E93
- long-term
 cardiovascular risk, deletion allele of ACE gene polymorphism and, 466–476
 colonic transit time in, 322–327
 cyclic intermittent etidronate effect on coronary artery calcification, 680–688
 endothelial progenitor cells in, 840–849
 portal-systemic encephalopathy related to, 3:E38
 predialysis serum bicarbonate levels, risk of mortality and hospitalization, 661–671
 for radiocontrast-induced nephropathy prophylaxis, 12–24
 religiosity effects on patient satisfaction and treatment adherence, 488–497
- removal of protein-bound solute p-cresol, 278–285
- reversal of dialysis dependency, stem cell transplantation for light chain deposition disease, 551–555
- short-daily, red blood cell survival in chronic renal failure, 715–719
- spontaneous mediastinal parathyroid autoinfarction after parathyroidectomy, 762–767
- vancomycin-resistant *Enterococcus* colonization, 337–343
- ventricular arrhythmias during and after, coronary stenosis and, 328–336
- Hemofiltration, for radiocontrast-induced nephropathy prophylaxis, 12–24
- Hemoglobin, international variations in anemia management of hemodialysis patients and, 94–111
- Hemolytic uremic syndrome
 FB21 as marker for glomerular endothelial cell injury in, 238–249
 mitomycin C-induced, circulating immune complexes and staphylococcal protein A immunosorption in, 4:E50
- Hemoperitoneum, in ANCA-associated polyangiitis syndrome, 908–911
- Hodgkin-Schönlein purpura nephritis
 FB21 as marker for glomerular endothelial cell injury in, 238–249
- IgG subclass deposition in, 42–49
- Hepatitis C infection
 with nephrotic syndrome, multiple renal lesions after interferon alfa therapy, 567–573
 proteinuria, renal insufficiency and, 924–929
- Herbal therapy, renal hazards from, 1–11
- Hereditary renal stone diseases, end-stage renal disease and, 799–805
- High-protein diet, effect on kidney and kidney disease, 950–962
- Hip fracture, in dialysis patients, increased risk of mortality and, 672–679

- Hispanics**
 access to renal transplantation, 334–352
 end-stage renal disease from focal segmental glomerulosclerosis and, 815–825
- Home hemodialysis**, pregnancy with nocturnal hemodialysis, 912–916
- Homocysteine**. *See also* Hyperhomocysteinemia
 asymptomatic cerebral lacunae in chronic kidney disease and, 35–41
 chronic kidney disease development and, 437–445
- Hospital-acquired acute renal failure**, in elderly, prognosis for, 410–419
- Hospitalization**
 of hemodialysis patients, water-soluble vitamin use and, 293–299
 risk predialysis serum bicarbonate levels and, 661–671
- Hypercalcemia**, immobilization, with prolonged anticoagulation in continuous renal replacement therapy, 1110–1114
- Hypercalciuria**, genetics of, 963–986
- Hyperhomocysteinemia**
 chronic kidney disease development and, 437–445
 inflammation and mortality in CKD patients starting hemodialysis, 455–465
- Hyperkalemia**
 ACE inhibitors or angiotensin receptor blockers in CAPD patients, 738–746
 herbal therapy and, 1–11
- Hyperlipidemia**
 fenofibrate-associated reversible allograft dysfunction in renal transplant recipients, 543–550
 gemfibrozil effect on renal function in men with chronic renal insufficiency and coronary disease, 832–839
- Hyperparathyroidism, secondary**
 cinacalcet pharmacokinetics, pharmacodynamics and safety in, 1070–1076
 effect of total parathyroidectomy on FGF-23 levels, 481–487
 histologic evaluation of bone disease after kidney transplantation and, 747–756
 MIBI scintigraphy in predicting response to calcitriol treatment, 476–480
 with renal insufficiency, FGF-23 and, 250–256
 spontaneous mediastinal parathyroid autoinfarction after parathyroidectomy, 762–767
- Hypertension**
 core curriculum in nephrology, 369–374
 effects of APD versus CAPD on, 132–145
 in ESRD, management by nephrologists versus cardiologists, 309–321
 herbal therapy and, 1–11
 in hyperuricemia, ESRD risk and, 642–650
 kidney disease awareness and, 185–197
 lipid enhancement of α_1 -adrenoreceptor pressor sensitivity in chronic kidney disease and, 446–454
 nephrosclerosis, diagnosis by renal biopsy in elderly patients, 618–626
 pregnancy induced, nocturnal hemodialysis for, 912–916
 relationship of cardiovascular risk factors with microalbuminuria, 25–34
- transplantation in diabetes mellitus with chronic kidney disease, 529–542
- Hyperuricemia**, as ESRD risk factor, 642–650
- Hyponatremia**, desmopressin acetate-related, 1:E3
- Hypotension**, anterior ischemic optic neuropathy in calcific uremic arteriolopathy, 6:E93
- Idiopathic membranous nephropathy**
 immunosuppressive therapy for, 385–401
 treatment of, 562–566
- Idiopathic nephrotic syndrome**, glomerular permeability activity in children, 604–610
- IgA nephropathy**
 exercise in young adult patients and, 257–263
 steroid-dependent with hematuria, evolved from minimal change disease, 773–777
- IgG nephropathy**, T helper subtype pattern in pathogenetic mechanism of, 42–49
- Immobilization hypercalcemia**, with prolonged anticoagulation in continuous renal replacement therapy, 1110–1114
- Immune complex glomerulonephritis**, interferon alfa for hepatitis C with nephrotic syndrome and, 567–573
- Immunoglobulin G**, subclasses, deposition in pediatric glomerulonephritis, 42–49
- Immunohistochemistry**, aquaporin 1 distribution/expression in peritoneum of PD patients, 146–154
- Immunosuppressive therapy**
 for breast cancer, crescentic glomerulonephritis and dense deposit disease with, 3:E33
 for idiopathic membranous nephropathy, 385–401
- In-center hemodialysis patients**
 adult, clinical performance measures for, 2:S–18–36
 pediatric, clinical performance measures for, 2:S15, 44–51
- Infections**. *See also* specific types of infections
 dialysis-catheter related bacteremia, 779–791
 vancomycin-resistant *Enterococcus* colonization in hemodialysis, 337–343
- Infection stones**, end-stage renal disease and, 799–805
- Inflammation**. *See also* C-reactive protein
 coronary artery calcification scores during peritoneal dialysis, 517–528
 hyperhomocysteinemia and mortality in CKD patients starting hemodialysis, 455–465
 resting energy expenditure in chronic kidney disease, 1008–1016
- Inherited epidermolysis bullosa**, renal disease mortality and, 651–660
- Insulin**, edematogenic properties of, 575–590
- Insulin resistance**, asymptomatic cerebral lacunae in chronic kidney disease and, 35–41
- Interferon alfa**, multiple renal lesions in hepatitis C infection with nephrotic syndrome, 567–573
- Interleukin-4**, IgG subclass deposition in glomerulonephritis and, 42–49
- Intermittent hemodialysis**, versus continuous for acute renal failure, 1000–1007
- Internet**, evaluation of eHealth web sites for chronic kidney disease patients, 71–76

- Interstitial nephritis
atazanavir-associated, 5:E81
chronic crystal-forming, tosufloxacin tosilate and, 902–907
telithromycin-induced, 2:E25
- Involuntary discharge, dialysis staff problems in dealing with difficult patients and, 893–901
- Iron
for anemia management of HD patients, international variations in, 94–111
intoxication, QT_c dispersion in peritoneal dialysis patients, 720–728
serum concentrations, dialysis membrane effects on, 509–516
- Ischemic optic neuropathy, in calcific uremic arteriolopathy, 6:E93
- Iso-osmolar agents, for radiocontrast-induced nephropathy prophylaxis, 12–24
- Kidney
function, resting energy expenditure in chronic kidney disease, 1008–1016
high-protein diet effects on, 950–962
- Kidney disease. *See also* specific types of kidney disease
diagnosis by renal biopsy in elderly patients, 618–626
high-protein diet effects on, 950–962
screening, in diabetic adults, 921–923
- Kidney stones, oxalate absorption and endogenous synthesis from ascorbate and, 1060–1069
- Kidney transplantation. *See also* Donor, kidney
adolescents with anemia of CKD, health-related quality of life and, 1017–1023
among American Indians and Hispanics, 334–352
assess for Canadian minorities with ESRD, 1083–1089
cyclosporin A, high-dose, for recurrent pediatric FSGS, 50–56
in diabetes mellitus with chronic kidney disease, 529–542
histologic evaluation of bone disease after, 747–756
late urinary tract infection after, 353–362
maintenance, conversion to C₂ monitoring of cyclosporine A exposure, 886–892
paired exchange, justification for, 1115–1120
recipient, rifabutin treatment of TB in, 4:E59
reversible fenofibrate-associated allograft dysfunction, 543–550
- Kinetics, effect of blood tubing sets on delivered dialyzer blood flow, 498–508
- Klebsiella pneumoniae*-related peritonitis, expanded-spectrum β-lactamase and, 6:E102
- Lacunar infarction, in chronic kidney disease, 35–41
- Left ventricle
mass, in young normotensive ADPKD patients, 216–223
overload in CKD, brain natriuretic peptide and, 420–428
- Leu64 Pro gene mutation, in apolipoprotein A-I amyloidosis, 1103–1109
- Light chain deposition disease, reversal of dialysis-dependent renal failure by stem cell transplantation, 551–555
- Linezolid deposition, after standard dose in critically ill CVVH patients, 1097–1102
- Lipid lowering therapy, progression of chronic kidney disease and, 917–920
- Lipids
α₁-adrenoreceptor pressor sensitivity in chronic kidney disease and, 446–454
in CRF, effect of n-3 PUFA on, 77–83
in HD patients, apolipoprotein E and, 300–308
in hemodialysis patients, apolipoprotein E and, 300–308 plasma, in CRF, effect of n-3 PUFA on, 77–83
- Loop diuretics, for acute renal failure, 402–409
- Low-molecular-weight heparin, dialysis membrane effects on serum levels, 509–516
- Low-turnover bone disease, after kidney transplantation, 747–756
- Lupus nephritis
class IV subclasses, 1050–1059
IgG subclass deposition in, 42–49
- Macroalbuminuria, in early stages of diabetes mellitus, 792–798
- Magnetic resonance imaging, preoperative renal volumes in predicting graft function in living donor transplantation, 877–885
- Malnutrition, and hyperhomocysteinemia, inflammation and mortality in CKD patients starting hemodialysis, 455–465
- Mantel cell lymphoma, with renal insufficiency, proteinuria, hematuria, hemiparesis and pleuritis, 1121–1125
- Maximum tubular reabsorptive rate of phosphate, fibroblast growth factor-23 in secondary hyperparathyroidism and, 250–256
- MDRD formula, validation for estimating GFR, 84–93
- Medial arterial calcification, mimicking temporal arteritis, 4:E73
- Medial smooth muscle cell injury, mechanism in diabetic nephropathy, 224–238
- Medical education. *See* Nephrology core curriculum
- Medicare, end-stage renal disease program, 2:S11
- Medullary cystic kidney disease, type I in large Native-American kindred, 611–617
- Membrane attack complex, medial smooth muscle cell injury in diabetic nephropathy and, 224–238
- Membranoproliferative glomerulonephritis (MPGN)
with adrenal ganglionoma, 363–368
early renal allograft dysfunction and
in elderly man, 1121–1125
IgG subclass deposition in, 42–49
- Membranous nephropathy
idiopathic, treatment of, 562–566
lack of monocytes in, 556–558
- Meta-analysis, effect of dialysis modality on plasma fibrinogen level, 941–949
- Microalbuminuria
cross-association with cardiovascular risk factors, 25–34
in early stages of diabetes mellitus, 792–798
- Middle molecules, removal by convective transport, 278–285
- Minimal change disease, evolving into steroid-dependent nephrotic syndrome with hematuria, 773–777
- Minorities
access to renal transplantation, 334–352

- with ESRD, access to renal transplantation in Canada, 1083–1089
- Mitomycin-C, hemolytic uremic syndrome induced by, circulating immune complexes and staphylococcal protein A immunosorption, 4:E50
- Mizoribine, for ANCA-associated renal vasculitis, 57–63
- Modification of Diet in Renal Disease formula, validation for estimating GFR, 84–93
- Molecular typing, vancomycin-resistant *Enterococcus* colonization in hemodialysis, 337–343
- Monocytes, lack of, in pulmonary renal syndrome, 556–558
- Morbidity, dialysis-related, multidisciplinary predialysis care and, 706–714
- Mortality**
- bacterial endocarditis in dialysis patients and, 1077–1082
 - cardiovascular, kidney disease as risk factor for, 198–206
 - dialysis-related, multidisciplinary predialysis care and, 706–714
 - of elderly with hospital-acquired versus community-acquired acute renal failure, 410–419
 - in hemodialysis
 - epoetin dose requirements and, 866–876
 - water-soluble vitamin use and, 293–299 - hyperhomocysteinemia and free amino acids in CKD patients starting hemodialysis, 455–465
 - late urinary tract infection after renal transplantation, 353–362
 - renal disease, inherited epidermolysis bullosa and, 651–660
 - restenosis rate after coronary angioplasty in renal insufficiency patients, 627–635
 - risk predialysis serum bicarbonate levels and, 661–671
- MPGN. *See* Membranoproliferative glomerulonephritis
- Multidetector spiral computed tomography, cyclic intermittent etidronate effect on coronary artery calcification in hemodialysis, 680–688
- Multidisciplinary predialysis care, morbidity/mortality and, 706–714
- Mutations**
- α -galactosidase A, in renal variant of Fabry disease, 5:E85
 - idiopathic renal calcium stones, hypercalcuria and, 963–986
 - Leu64 Pro, in apolipoprotein A-I amyloidosis, 1103–1109
 - NPHS2, in siblings with steroid-resistant nephrotic syndrome, 2:E22
 - SLC4A1*, in autosomal recessive distal renal tubular acidosis, 64–70
- Myocardial infarction**
- restenosis rate after coronary angioplasty in renal insufficiency patients, 627–635
 - risk
 - deletion allele of ACE gene polymorphism in long-term hemodialysis and, 466–476
 - kidney disease as risk factor for, 198–206
- Na⁺-phosphate cotransporter**, in monogenic renal calcium stone-related disorders, 963–986
- National Health and Nutrition Examination Surveys (NHANES), findings for 1999–2000, 185–197
- National Institute of Mental Health Diagnostic Interview Schedule, evaluation of depression mortality risk in CKD with heart failure, 207–215
- Native-American kindred, medullary cystic kidney disease type I in, 611–617
- Needle biopsy, abnormalities in elderly patients, 618–626
- Nephrectomy, laparoscopic, of xanthogranulomatous pyelonephritis in anephric patient, 930–936
- Nephrocalcinosis, genetics of, 963–986
- Nephrolithiasis
- calcium, genetics of, 963–986
 - end-stage renal disease and, 799–805
 - oxalate absorption and endogenous synthesis from ascorbate, 1060–1069
- Nephrologists, cardiovascular disease management in ESRD, 309–321
- Nephrology core curriculum, economics of clinical nephrology practice, 168–178
- Nephropathy**
- albuminuria in early stages of diabetes mellitus, 792–798
 - gemfibrozil effect on renal function in men with chronic renal insufficiency and coronary disease, 832–839
- Nephropathy practice, economics, core curriculum in nephrology, 168–178
- Nephrotic syndrome**
- immunosuppressive therapy for idiopathic membranous nephropathy, 385–401
 - membranoproliferative glomerulonephritis with adrenal ganglioneuroma, 363–368
 - with pulmonary alveolar proteinosis, lack of monocytes and, 556–558
 - steroid-dependent with hematuria, evolved from minimal change disease, 773–777
 - steroid-resistant, of siblings with NPHS2 gene mutation, 2:E22
- Nephrotoxicity, herbal therapy and, 1–11
- NHANES, findings for 1999–2000, 185–197
- Nitric oxide synthesis, ENOS polymorphism effects in non-diabetic hemodialysis patients, 112–120
- Nocturnal hemodialysis
- pregnancy with, 912–916
 - red blood cell survival in chronic renal failure, 715–719
- Nonenesterified fatty acids, α_1 -adrenoreceptor pressor sensitivity in chronic kidney disease and, 446–454
- Non-Langerhans cell histiocytes, chronic crystal-forming interstitial nephritis, tosulfoxacin tosilate and, 902–907
- Obstructive sleep apnea, night and day proteinuria in, 636–641
- Osteoporosis, in CRRT with citrate anticoagulation, 1110–1114
- Osteoprotegerin, cyclic intermittent etidronate effect on coronary artery calcification in hemodialysis, 680–688
- Outcome, kidney disease as risk factor for recurrent cardiovascular disease, 198–206
- Oxalate, absorption and endogenous synthesis from ascorbate in stone formers versus non-stone formers, 1060–1069

- Oxidative stress, tyrosine nitration in long-term hemodialysis, 286–292
- Pancreas transplantation, in diabetes mellitus with chronic kidney disease, 529–542
- Parathyroidectomy
- FGF-23 levels in secondary hyperparathyroidism and, 481–487
 - spontaneous mediastinal parathyroid autoinfarction after, 762–767
- Parathyroid gland, response to calcitriol treatment, MIBI scintigraphy prediction of, 476–480
- Parathyroid hormone. *See also* Hyperparathyroidism
- fibroblast growth factor-23 in secondary hyperparathyroidism and, 250–256
- Parenchymal crystal deposits, end-stage renal disease and, 799–805
- Patient behavioral definitions, dialysis staff problems in dealing with difficult patients and, 893–901
- Patient education, evaluation of eHealth web sites for chronic kidney disease patients, 71–76
- Patient preferences, for dialysis modalities and doses, 695–705
- Patient satisfaction, religiosity in hemodialysis population and, 488–497
- p-Cresol, removal by convective transport, 278–285
- PD. *See* Peritoneal dialysis
- Pediatric patients
- glomerular permeability activity in idiopathic nephrotic syndrome, 604–610
 - with glomerulonephritis, IgG subclass deposition in, 42–49
 - in-center hemodialysis, clinical performance measures for, 2:S15, 44–51
 - with recurrent FSGS, high-dose oral cyclosporin therapy for, 50–56
- Peptide excretion, in renal disease patients, 1031–1038
- Peritoneal dialysis (PD). *See also* specific peritoneal dialysis modalities
- aquaporin 1 distribution/expression in peritoneum, 146–154
 - Asia bogorensis* peritonitis identified by 16S ribosomal RNA sequence analysis, 2:E15
 - automated versus continuous ambulatory, 132–145
 - clinical performance measures, 2:S36–44
 - coronary artery calcification score trends and dynamics, 517–528
 - effect on plasma fibrinogen level, 941–949
 - effects of iron stores on QT_c dispersion, 720–728
 - long-term, colonic transit time in, 322–327
- Peritoneal equilibrium test, effects of ACE inhibitors or angiotensin receptor blockers on potassium in CAPD patients, 738–746
- Peritonitis
- Asia bogorensis*, identified by 16S ribosomal RNA sequence analysis, 2:E15
 - encapsulating peritoneal sclerosis in Japan and, 729–737
 - Klebsiella pneumoniae*-related, expanded-spectrum β-lactamase and, 6:E102
 - peritoneal dialysis-related
 - antimicrobial prevention of, 591
- reevaluation of empiric therapy for, 559–561
- Pharmacodynamics, of cinacalcet, 1070–1076
- Pharmacokinetics
- of cinacalcet, 1070–1076
 - linezolid deposition after standard dose in critically ill CVVH patients, 1097–1102
- Phenylephrine, pressure sensitivity in chronic kidney disease and, 446–454
- Phosphate, fibroblast growth factor-23 in secondary hyperparathyroidism and, 250–256
- Plaque progression, coronary artery calcification in predialysis CRF patients and, 1024–1030
- Plasma proteins, tyrosine nitration in long-term hemodialysis, 286–292
- Platelet contractile force, enoxaparin anticoagulant activity in ESRD and, 270–277
- Pleuritis, in elderly man with membranoproliferative glomerulonephritis, 1121–1125
- Polyangiitis, hemoperitoneum in ANCA-associated polyangiitis syndrome, 908–911
- Poly cystic kidney disease, exercise blood pressure, cardiac structure and diastolic function in normotensive patients, 216–223
- Polymerase chain reaction, urotransferrin II and urotransferrin II receptor expression in diabetic nephropathy, 826–831
- Polymorphisms
- ACE gene deletion allele, cardiovascular risk and, 466–476
 - ApoE, lipid levels in hemodialysis patients and, 300–308
 - ENOS, cardiovascular events in nondiabetic hemodialysis patients and, 112–120
- Polysomnography, of proteinuria in obstructive sleep apnea, 636–641
- n-3-Polyunsaturated fatty acids, effect on plasma lipids, lipoproteins and blood pressure in CRF, 77–83
- Portal-systemic encephalopathy, hemodialysis-related, 3:E38
- Potassium, in CAPD patients, effects of ACE inhibitors or angiotensin receptor blockers on, 738–746
- Predialysis care, multidisciplinary, morbidity/mortality and, 706–714
- Predialysis patients, with chronic renal failure, coronary artery calcification in, 1024–1030
- Prediction equations, glomerular filtration rate, validation of, 84–93
- Preemptive therapy, for ANCA-associated renal vasculitis, 57–63
- Pregnancy
- with nocturnal hemodialysis, 912–916
 - Weber's granulomatosis in, 4:E68
- Prognosis
- of acute renal failure in hospitalized elderly, 410–419
 - of chronic kidney disease, brain natriuretic peptide and, 420–428
 - glomerular permeability activity in children with idiopathic nephrotic syndrome, 604–610
- Progression, of chronic kidney disease, lipid-lowering therapy and, 917–920
- Propofol infusion syndrome, renal failure of, 6:E98
- Prospective study
- APD versus CAPD, 132–145

- cardiovascular events in nondiabetic HD patients, *ENOS* polymorphism and, 112–120
 encapsulating peritoneal sclerosis in Japan, 729–737
- Protein**
 bound solutes, removal by convective transport, 278–285
 excretion, in renal disease patients, 1031–1038
 high-dietary levels, effect on kidney and kidney disease, 950–962
- Proteinuria**
 in elderly man with membranoproliferative glomerulonephritis, 1121–1125
 high-protein diets and, 950–962
 in IgA nephropathy, exercise and, 257–263
 night and day in sleep apnea patients, 636–641
 and predicted creatinine clearance, ESRD risk and, 806–814
 in recurrent pediatric FSGS, high-dose cyclosporin A for, 50–56
- Pulmonary edema, insulin-induced, 575–590
- Pulmonary renal syndrome, lack of monocytes in, 556–558
- Pure red cell aplasia
 epoetin alfa therapy, anti-EPO antibody levels after, 264–269
 resumption of epoetin alfa after rituximab treatment, 757–761
- Purine synthesis inhibitor, for ANCA-associated renal vasculitis, 57–63
- Pyelonephritis, after renal transplantation, 353–362
- Q_{cT} dispersion, effect on iron stores in PD patients, 720–728
- Race**
 assess to kidney transplantation in Canada, 1083–1089
 end-stage renal disease from focal segmental glomerulosclerosis and, 815–825
 kidney disease awareness and, 185–197
- Radiocontrast-induced nephropathy, prevention of, 12–24
- Radioimmunoprecipitation assay, anti-EPO antibody levels in CKD after epoetin alfa therapy, 264–269
- Ramipril, exercise in IgA nephropathy and, 257–263
- Randomized controlled trials. *See* specific randomized controlled trials
 antimicrobial therapy to prevent peritoneal dialysis-induced peritonitis, 591–603
 Cochrane Renal Group Report, 768–772
 dimercaptosuccinic acid for hyperhomocysteinemia in HD, 689–694
 gemfibrozil effect on renal function in men with CRI and coronary disease, 832–839
- ReadySet blood tubing set, delivered dialyzer blood flow and, 498–508
- Recombinant human erythropoietin. *See* Erythropoietin
- Red blood survival, in chronic renal failure, 715–719
- Religiosity, in hemodialysis population, 488–497
- Renal biopsy abnormalities, in elderly patients, 618–626
- Renal failure/insufficiency. *See* Acute renal failure; Chronic kidney disease
- Renal osteodystrophy, after kidney transplantation, 747–756
- Renal replacement therapy. *See* specific renal replacement therapies
- Renal satellite units, clinical and cost evaluation of HD in, 121–131
- Renal transplantation. *See* Kidney transplantation
- Renal volumes, preoperative in predicting graft function in living donor transplant, 877–885
- Residual renal function, APD versus CAPD, 132–145
- Restenosis, rate after coronary angioplasty in renal insufficiency patients, 627–635
- Resting energy expenditure, of chronic kidney disease patients, 1008–1016
- Rhabdomyolysis, in propofol infusion syndrome, 6:E98
- Rifabutin, for tuberculosis in kidney transplant recipient, 4:E59
- Rituximab, for pure red cell aplasia, resumption of epoetin alfa after, 757–761
- RNA sequence analysis, identification of *Asia bogorensis* peritonitis, 2:E15
- Safety, of cinacalcet, 1070–1076
- Saline hydration, for radiocontrast-induced nephropathy prophylaxis, 12–24
- Secondary hyperparathyroidism. *See* Hyperparathyroidism, secondary
- Sepsis, late urinary tract infection after renal transplantation, 353–362
- Sex**
 end-stage renal disease from focal segmental glomerulosclerosis and, 815–825
 kidney disease awareness and, 185–197
- Short-daily hemodialysis, red blood cell survival in chronic renal failure, 715–719
- Siblings, with steroid-resistant nephrotic syndrome, NPHS2 gene mutations in, 2:E22
- Sieving coefficient, linezolid deposition after standard dose in critically ill CVVH patients, 1097–1102
- Simplified Acute Physiology Scores, high-dose furosemide for acute renal failure, 402–409
- SLC4A1* mutations, in Thai patients with autosomal recessive distal renal tubular acidosis, 64–70
- Sleep apnea, night and day proteinuria in, 636–641
- α-Smooth muscle actin, in nodular glomerulosclerosis in Chinese patients with type 2 diabetes, 1039–1049
- Sodium, renal handling, insulin and, 575–590
- Sodium dip, aquaporin 1 distribution/expression in peritoneum of PD patients and, 146–154
- Sodium removal, time profiles, APD versus CAPD, 132–145
- Soluble interleukin-2 receptor (sIL-2R), IgG subclass deposition in glomerulonephritis and, 42–49
- Southeast Asian ovalocytosis, with autosomal recessive distal renal tubular acidosis, *SLC4A1* mutations in, 64–70
- Spiral computed tomography, of coronary artery calcification in predialysis CRF patients, 1024–1030
- Spirituality, in hemodialysis population, 488–497
- Spontaneous remission, of secondary hyperparathyroidism, mediastinal parathyroid autoinfarction and, 762–767
- Squamous cell carcinoma in situ, at exit site of tunneled catheter, 3:43
- Staphylococcal protein A immunosorption in, in mitomycin C-induced hemolytic uremic syndrome, 4:E50
- Stem cell transplantation, autologous, for light chain deposition disease, 551–555
- Steroids**
 minimal change disease evolving into nephrotic syndrome with hematuria, 773–777

- resistant nephrotic syndrome, of siblings with NPHS2 gene mutation, 2:E22
- Stroke risk**
deletion allele of ACE gene polymorphism in long-term hemodialysis and, 466–476
kidney disease as risk factor for, 198–206
- Struvite stones**, end-stage renal disease and, 799–805
- Survival**
high-dose furosemide for acute renal failure, 402–409
immunosuppressive therapy for idiopathic membranous nephropathy, 385–401
late urinary tract infection after renal transplantation, 353–362
long-term, bacterial endocarditis in dialysis patients and, 1077–1082
patients' preferences in choice of dialysis modality and dose, 695–705
- Systematic review**
Cochrane Renal Group Report, 768–772
immunosuppressive therapy for idiopathic membranous nephropathy, 385–401
of randomized controlled trials on antimicrobial therapy to prevent peritoneal dialysis-induced peritonitis, 591–603
- Tamm-Horsfall protein, in uromodulin storage diseases, 987–999
- Technetium Tc 99m-sestamibi scintigraphy, prediction of calcitriol treatment response, 476–480
- Telithromycin, interstitial nephritis induced by, 2:E25
- Temporal arteritis, mimicked by medial arterial calcification, 4:E73
- Thai patients, with autosomal recessive distal renal tubular acidosis, *SLC4A1* mutations in, 64–70
- T helper cell subsets, IgG subclass deposition in glomerulonephritis and, 42–49
- Themodilution technique, effect of fistula banding on access flow and cardiac output, 1090–1096
- Thiazolidinediones, edemamrogenic properties of insulin and, 575–590
- Thrombin generation time, enoxaparin anticoagulant activity in ESRD, 270–277
- Thrombotic microangiopathy, hepatitis C, proteinuria and renal insufficiency in, 924–929
- Tosufloxacin tosilate, crystal-forming chronic interstitial nephritis and, 902–907
- Transferrin saturation, effects of iron stores on QT_c dispersion in PD patients, 720–728
- Transforming growth factor- β , in nodular glomerulosclerosis with diabetes, 1039–1049
- Transjugular renal biopsy, in acute renal failure, hemodialysis catheter placement and, 429–436
- Tuberculosis, rifabutin treatment in kidney transplant recipient, 4:E59
- Tubular degradation, urinary peptide excretion in renal disease patients, 1031–1038
- Tyrosine nitration, in long-term hemodialysis, 286–292
- Ultrafiltration**
aquaporin 1 distribution/expression in peritoneum of PD patients and, 146–154
- for radiocontrast-induced nephropathy prophylaxis, 12–24
- time profiles, APD versus CAPD, 132–145
- United Network for Organ sharing**, justification for paired exchange, 1115–1120
- Uric acid, hyperuricemia as ESRD risk factor, 642–650
Uric acid nephrolithiasis, end-stage renal disease and, 799–805
- Urinary tract infections**
late, after renal transplantation, 353–362
xanthogranulomatous pyelonephritis in anephric patient, 930–936
- Uromodulin storage diseases**, clinical aspects and mechanisms of, 987–999
- Urotensin II, in diabetic nephropathy, 826–831
- Urotensin II receptor, in diabetic nephropathy, 826–831
- US Renal Data System (USRDS)**, late urinary tract infection after renal transplantation, 353–362
- Validation**, of MDRD formula for estimating glomerular filtration rate, 84–93
- Vancomycin-resistant *Enterococcus***, colonization in hemodialysis, 337–343
- Vascular access**. *See also* specific vascular access methods
blood flow, surgical banding of arteriovenous fistula and, 1090–1096
dialysis-catheter related bacteremia and, 779–791
intra-access blood flow in under-arm native AVF, 850–858
in pediatric patients in-center hemodialysis, 2:S45–48
stenosis, comparison of arteriovenous grafts and fistulas, 859–865
- Vascular calcification**. *See* Coronary artery calcification
- Vascular complications**, in diabetes mellitus, 575–590
- Vascular endothelial growth factor**, endothelial progenitor cells in long-term HD, 840–849
- Vasculitis**, hemoperitoneum in ANCA-associated polyangiitis syndrome, 908–911
- Vasculitis**, renal, ANCA-associated, mizoribine for, 57–63
- VEGF**, endothelial progenitor cells in long-term hemodialysis, 840–849
- Ventricular arrhythmias**, during and after hemodialysis, coronary stenosis and, 328–336
- Vitamin D receptor**, in monogenic renal calcium-stone disorders, 963–986
- Vitamins**
ascorbate, oxalate absorption and endogenous synthesis from, 1060–1069
water-soluble, use by hemodialysis patients, mortality/hospitalization and, 293–299
- Web sites**, eHealth, evaluation for chronic kidney disease patients, 71–76
- Wegener's granulomatosis**, in pregnancy, 4:E68
- Weight gain**, insulin-induced, 575–590
- Weight loss diets**, high-protein, effect on kidney and kidney disease, 950–962
- White blood cell count**, microalbuminuria and, 25–34
- Women**, late urinary tract infection after renal transplantation, 353–362
- Xanthogranulomatous pyelonephritis**, in anephric patient, 930–936